Flu Vaccines Reduced Severe Disease and Mortality
A new systematic review highlights the efficacy of annual vaccination in protecting older adults and children from hospitalization.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Do you trust influenza vaccine recommendations issued without the guidance of federal advisory committees?
A systematic review of 69 studies has confirmed that influenza vaccines significantly lower the risk of severe disease and death across various age groups. The findings, which informed guidance for the 2026-2027 respiratory season, underscore the ongoing clinical value of seasonal immunization.
Why it matters
Understanding vaccine effectiveness helps patients and clinicians make informed decisions about seasonal protection strategies. As respiratory seasons shift, this evidence supports the role of vaccination in reducing the public health burden of hospitalizations and mortality.
This systematic review synthesized 21 randomized trials and 48 other studies to evaluate flu vaccine performance. While effectiveness varied, results showed a 43.6% relative advantage for high-dose vaccines in older adults versus standard doses.
The players
US Department of Health and Human Services
The federal agency responsible for overseeing public health, medical research, and vaccination policy in the United States.
Advisory Committee on Immunization Practices
An expert body that provides federal recommendations for vaccine use in the United States.
The details
Influenza vaccines work by training the immune system to recognize and neutralize specific viral strains identified as likely to circulate. The review noted that while the mRNA-1010 vaccine was licensed in August 2026, it was associated with a higher incidence of Grade 3 reactions (6.4%) compared to traditional standard-dose formulations (1.0%).
Timeline
August 1, 2025 - June 30, 2026: Timeframe of studies analyzed in the review.
2025-2026 season: Period of CDC surveillance for flu-related medical visits.
August 2026: Licensing of the mRNA-1010 vaccine in the United States.
2026-2027 season: Respiratory period for which recommendations were prepared.
Health Landscape
This research builds upon the massive DANFLU-2 trial to confirm the continued utility of established flu vaccination protocols. It marks a shift toward more granular effectiveness data as newer platforms like mRNA-1010 are introduced to the existing immunization landscape.
Flu vaccines remain a primary tool for reducing hospitalization risk, particularly for older adults and pediatric populations. It is worth discussing with your doctor which specific vaccine formulation is appropriate for your age and health history before the current respiratory season.
The takeaway
Annual influenza vaccination remains highly effective at preventing severe illness and death across the population. Readers should track the timing of local immunization drives and consult their physician about the best vaccine options for their specific needs.
Further reading
For more on managing respiratory health, see the Asthma section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust influenza vaccine recommendations issued without the guidance of federal advisory committees?
